Latest Valeant Pharmaceuticals International (VRX)
Post# of 193
Posted On: 03/14/2014 10:10:53 PM
Latest Valeant Pharmaceuticals International (VRX) Headlines
New York, New York! $5 Billion in Active Life Science Capital Investment, an Industrial Info News Alert
Marketwire - Fri Mar 14, 5:30AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- As Sinatra sang so many years ago, "...start spreading the news." In this case, the news would be the $5 billion worth of active life science capital investment in the state of New York. Divided among 73 projects in various stages of planning, engineering and construction, the projects underscore the state's importance within the industry.
Three Leading Growth Names Pull Back To Key Support Level
at Investor's Business Daily - Wed Mar 12, 6:01PM CDT
Base breakouts aren't as plentiful as they were, but pullbacks to the 10-week moving average for the first time after a breakout are, as evidenced by today's Stock Spotlight screen. Big Data firm Tableau Software (DATA) looks poised for a test of its...
Can Valeant Continue This Growth?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:00PM CDT
Canada's Valeant Pharmaceuticals is a good example of what can be done when a company chooses to go its own way and zig while others zag. In an industry that had becoming increasingly skittish about mergers and acquisitions as a growth driver,...
Greenberg: What You May Have Missed
at The Street - Wed Mar 12, 8:33AM CDT
What you may have missed, including takes on Nu Skin, Clean Harbors and pharmaceutical mega mergers. It was a light week as I am working on new stories, but here is a roundup from last week's Reality Check. Plus, as an added bonus, there is a new red...
Valeant Pharmaceuticals International Earnings Hindsight: Down 4.5% in Last 11 Days (VRX)
Comtex SmarTrend(R) - Mon Mar 10, 7:28AM CDT
A week ago on February 27th, 2014 Valeant Pharmaceuticals International (NYSE:VRX) reported earnings and analysts, on average, expected earnings of $2.06 on sales of $2.1 billion. Valeant Pharmaceuticals International actually reported earnings of $2.15 per share on sales of $2.1 billion, beating EPS estimates by $0.09 and beating revenue estimates by $4.8 million. Shares of Valeant Pharmaceuticals International have slipped from $148.00 to $141.37, representing a loss of 4.5%, since the company reported earnings 11 days ago.
Valeant Pharmaceuticals Hit By Budget Tax Clause
at Investor's Business Daily - Fri Mar 07, 5:00PM CST
Valeant Pharmaceuticals (VRX) took a 5% hit in heavy trade Thursday, potentially linked to a clause included in the $3.9 trillion budget the Obama administration delivered to Congress Tuesday. The budget item apparently seeks to exclude tax...
Nasdaq Lags As Stock Market Closes Lower
at Investor's Business Daily - Fri Mar 07, 3:28PM CST
Stocks closed mixed as a better-than-expected jobs report failed to hold the market's interest. Indexes opened higher after the Labor Department reported an increase of 175,000 jobs in February, while the unemployment rate edged up to 6.7%. But the...
Early Gains Fade; E-House Breaks Out But Biotechs Stumble
at Investor's Business Daily - Fri Mar 07, 2:33PM CST
Enthusiasm was short-lived in the stock market after Friday's better-than-expected jobs report. All three major averages were near session lows after early strength. With a little over one hour remaining in the session, selling was most pronounced in...
Stock Market Closes Mixed; Ambarella Tops Expectations
at Investor's Business Daily - Thu Mar 06, 4:00PM CST
Stocks closed mixed Thursday, and after the bell Ambarella (AMBA) topped profit expectations. Ambarella, a maker of video chips, reported a 27% jump in sales to $40 million for the January-ended quarter. Adjusted earnings of 26 cents a share were...
Stock Market Closes Mixed; Medical Leaders Drop
at Investor's Business Daily - Thu Mar 06, 3:13PM CST
Stocks closed mixed Thursday as the medical sector, one of the market's bulwarks, came under some selling. The Dow Jones industrial average led with a 0.4% gain, while the S&P 500 added 0.2% and the Nasdaq fell 0.2%. Volume fell across the board,...
Insider Trading Alert - BIIB, VRX And AME Traded By Insiders
at The Street - Thu Mar 06, 12:00PM CST
Stocks with insider trader activity include BIIB, VRX and AME
Uptrend Call Working As Valeant Pharmaceuticals International Stock Rises 28.3% (VRX)
Comtex SmarTrend(R) - Wed Mar 05, 5:09PM CST
SmarTrend identified an Uptrend for Valeant Pharmaceuticals International (NYSE:VRX) on December 26th, 2013 at $113.12. In approximately 2 months, Valeant Pharmaceuticals International has returned 28.30% as of today's recent price of $145.13.
Smile Brands Names Health Care Industry Veteran as President and CEO
Business Wire - Wed Mar 05, 10:00AM CST
Smile Brands Inc., one of the nation's leading providers of business support services to dental groups in the United States, today announced that its Board of Directors has appointed Dan Wechsler as president and chief executive officer. Wechsler previously held the position of executive vice president and company group chairman for Valeant Pharmaceuticals (NYSE:VRX).
Can Allergan's Growth Continue?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In the world of Big Pharma, growth is a precious commodity these days. Allergan is a noteworthy exception, though, as the company continues to see strong demand for cornerstone products like Botox an Restasis, as well as its facial aesthetics...
Drugmakers Actavis, Biogen, Valeant Hold Near Highs
at Investor's Business Daily - Tue Mar 04, 4:13PM CST
Names in the Stock Spotlight enjoyed a strong day Tuesday as the market rallied on news the Ukraine crisis was defused, at least for now. Most of the stocks are well extended from buy points, but should be watched to see if they can give investors a...
QLT Narrows Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:00AM CST
The narrower loss was due to the lower costs incurred by QLT in the final quarter of 2013.
Look for Shares of Valeant Pharmaceuticals International to Potentially Rebound after Yesterday's 1.02% Sell Off
Comtex SmarTrend(R) - Mon Mar 03, 4:50PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $140.55 to a high of $143.90. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $143.11 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Greenberg: Buffett Tells Investors to Get Real About EBITDA
at The Street - Sun Mar 02, 11:47AM CST
The best part about Berkshire Hathaway CEO Warren Buffett's annual investor letters is that they always provide some kind of reality check.This year, in one sentence, he takes on one of the biggest diversion tactics of all -- one promulgated by many...
Valeant Beats Earnings & Revs in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:49AM CST
Valeant reported fourth quarter 2013 cash earnings per share of $2.15, up from the year-ago earnings of 1.22 per share.
New York, New York! $5 Billion in Active Life Science Capital Investment, an Industrial Info News Alert
Marketwire - Fri Mar 14, 5:30AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- As Sinatra sang so many years ago, "...start spreading the news." In this case, the news would be the $5 billion worth of active life science capital investment in the state of New York. Divided among 73 projects in various stages of planning, engineering and construction, the projects underscore the state's importance within the industry.
Three Leading Growth Names Pull Back To Key Support Level
at Investor's Business Daily - Wed Mar 12, 6:01PM CDT
Base breakouts aren't as plentiful as they were, but pullbacks to the 10-week moving average for the first time after a breakout are, as evidenced by today's Stock Spotlight screen. Big Data firm Tableau Software (DATA) looks poised for a test of its...
Can Valeant Continue This Growth?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Mar 12, 1:00PM CDT
Canada's Valeant Pharmaceuticals is a good example of what can be done when a company chooses to go its own way and zig while others zag. In an industry that had becoming increasingly skittish about mergers and acquisitions as a growth driver,...
Greenberg: What You May Have Missed
at The Street - Wed Mar 12, 8:33AM CDT
What you may have missed, including takes on Nu Skin, Clean Harbors and pharmaceutical mega mergers. It was a light week as I am working on new stories, but here is a roundup from last week's Reality Check. Plus, as an added bonus, there is a new red...
Valeant Pharmaceuticals International Earnings Hindsight: Down 4.5% in Last 11 Days (VRX)
Comtex SmarTrend(R) - Mon Mar 10, 7:28AM CDT
A week ago on February 27th, 2014 Valeant Pharmaceuticals International (NYSE:VRX) reported earnings and analysts, on average, expected earnings of $2.06 on sales of $2.1 billion. Valeant Pharmaceuticals International actually reported earnings of $2.15 per share on sales of $2.1 billion, beating EPS estimates by $0.09 and beating revenue estimates by $4.8 million. Shares of Valeant Pharmaceuticals International have slipped from $148.00 to $141.37, representing a loss of 4.5%, since the company reported earnings 11 days ago.
Valeant Pharmaceuticals Hit By Budget Tax Clause
at Investor's Business Daily - Fri Mar 07, 5:00PM CST
Valeant Pharmaceuticals (VRX) took a 5% hit in heavy trade Thursday, potentially linked to a clause included in the $3.9 trillion budget the Obama administration delivered to Congress Tuesday. The budget item apparently seeks to exclude tax...
Nasdaq Lags As Stock Market Closes Lower
at Investor's Business Daily - Fri Mar 07, 3:28PM CST
Stocks closed mixed as a better-than-expected jobs report failed to hold the market's interest. Indexes opened higher after the Labor Department reported an increase of 175,000 jobs in February, while the unemployment rate edged up to 6.7%. But the...
Early Gains Fade; E-House Breaks Out But Biotechs Stumble
at Investor's Business Daily - Fri Mar 07, 2:33PM CST
Enthusiasm was short-lived in the stock market after Friday's better-than-expected jobs report. All three major averages were near session lows after early strength. With a little over one hour remaining in the session, selling was most pronounced in...
Stock Market Closes Mixed; Ambarella Tops Expectations
at Investor's Business Daily - Thu Mar 06, 4:00PM CST
Stocks closed mixed Thursday, and after the bell Ambarella (AMBA) topped profit expectations. Ambarella, a maker of video chips, reported a 27% jump in sales to $40 million for the January-ended quarter. Adjusted earnings of 26 cents a share were...
Stock Market Closes Mixed; Medical Leaders Drop
at Investor's Business Daily - Thu Mar 06, 3:13PM CST
Stocks closed mixed Thursday as the medical sector, one of the market's bulwarks, came under some selling. The Dow Jones industrial average led with a 0.4% gain, while the S&P 500 added 0.2% and the Nasdaq fell 0.2%. Volume fell across the board,...
Insider Trading Alert - BIIB, VRX And AME Traded By Insiders
at The Street - Thu Mar 06, 12:00PM CST
Stocks with insider trader activity include BIIB, VRX and AME
Uptrend Call Working As Valeant Pharmaceuticals International Stock Rises 28.3% (VRX)
Comtex SmarTrend(R) - Wed Mar 05, 5:09PM CST
SmarTrend identified an Uptrend for Valeant Pharmaceuticals International (NYSE:VRX) on December 26th, 2013 at $113.12. In approximately 2 months, Valeant Pharmaceuticals International has returned 28.30% as of today's recent price of $145.13.
Smile Brands Names Health Care Industry Veteran as President and CEO
Business Wire - Wed Mar 05, 10:00AM CST
Smile Brands Inc., one of the nation's leading providers of business support services to dental groups in the United States, today announced that its Board of Directors has appointed Dan Wechsler as president and chief executive officer. Wechsler previously held the position of executive vice president and company group chairman for Valeant Pharmaceuticals (NYSE:VRX).
Can Allergan's Growth Continue?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Mar 04, 5:30PM CST
In the world of Big Pharma, growth is a precious commodity these days. Allergan is a noteworthy exception, though, as the company continues to see strong demand for cornerstone products like Botox an Restasis, as well as its facial aesthetics...
Drugmakers Actavis, Biogen, Valeant Hold Near Highs
at Investor's Business Daily - Tue Mar 04, 4:13PM CST
Names in the Stock Spotlight enjoyed a strong day Tuesday as the market rallied on news the Ukraine crisis was defused, at least for now. Most of the stocks are well extended from buy points, but should be watched to see if they can give investors a...
QLT Narrows Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 9:00AM CST
The narrower loss was due to the lower costs incurred by QLT in the final quarter of 2013.
Look for Shares of Valeant Pharmaceuticals International to Potentially Rebound after Yesterday's 1.02% Sell Off
Comtex SmarTrend(R) - Mon Mar 03, 4:50PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $140.55 to a high of $143.90. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $143.11 on volume of 2.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Greenberg: Buffett Tells Investors to Get Real About EBITDA
at The Street - Sun Mar 02, 11:47AM CST
The best part about Berkshire Hathaway CEO Warren Buffett's annual investor letters is that they always provide some kind of reality check.This year, in one sentence, he takes on one of the biggest diversion tactics of all -- one promulgated by many...
Valeant Beats Earnings & Revs in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:49AM CST
Valeant reported fourth quarter 2013 cash earnings per share of $2.15, up from the year-ago earnings of 1.22 per share.
(0)
(0)Bausch Health Companies Inc. (BHC) Stock Research Links
Scroll down for more posts ▼